Journal
CANCERS
Volume 12, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/cancers12113451
Keywords
adipose tissue; colorectal neoplasms; cholecalciferol; mediation; prognosis; randomized; skeletal muscle
Categories
Funding
- National Cancer Institute of the National Institutes of Health [R00-CA218603, R25-CA203650, P50CA127003, R01CA205406, R01CA118553]
- National Institute of General Medicine Sciences of the National Institutes of Health [U54-GM104940]
- National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [P30-DK072476]
- Gloria Spivak Faculty Advancement Award
- Friends of Dana-Farber Cancer Institute Award
- Project P Fund, Douglas Gray Woodruff Chair fund
- Consano, Pharmavite LLC
- Genentech
Ask authors/readers for more resources
Simple Summary Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. It is unknown if high-dose vitamin D-3 impacts skeletal muscle and adipose tissue, as compared with standard-dose vitamin D-3, in patients with advanced or metastatic colorectal cancer. In this exploratory analysis of a phase II randomized trial, high-dose vitamin D-3 did not lead to changes of body weight, body mass index, muscle area, muscle attenuation, visceral adipose tissue area, or subcutaneous adipose tissue area, as compared with standard-dose vitamin D-3. High-dose vitamin D-3 did not change body composition in patients receiving chemotherapy for advanced or metastatic colorectal cancer. Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. In this exploratory analysis of a double-blind, multicenter, randomized phase II clinical trial, 105 patients with advanced or metastatic colorectal cancer who were receiving chemotherapy were randomized to either high-dose vitamin D-3 (4000 IU) or standard-dose (400 IU) vitamin D-3. Body composition was measured with abdominal computed tomography at enrollment (baseline) and after cycle 8 of chemotherapy (16 weeks). As compared with standard-dose vitamin D-3, high-dose vitamin D-3 did not significantly change body weight [-0.7 kg; (95% CI: -3.5, 2.0)], body mass index [-0.2 kg/m(2); (95% CI: -1.2, 0.7)], muscle area [-1.7 cm(2); (95% CI: -9.6, 6.3)], muscle attenuation [-0.4 HU; (95% CI: -4.2, 3.2)], visceral adipose tissue area [-7.5 cm(2); (95% CI: -24.5, 9.6)], or subcutaneous adipose tissue area [-8.3 cm(2); (95% CI: -35.5, 18.9)] over the first 8 cycles of chemotherapy. Among patients with advanced or metastatic colorectal cancer, the addition of high-dose vitamin D-3, vs standard-dose vitamin D-3, to standard chemotherapy did not result in any changes in body composition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available